Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology
Zoeb Jiwaji, Sachin S. Tiwari, Rolando Xavier Aviles‐Reyes, Monique Hooley, David W. Hampton, Megan Torvell, Delinda A. Johnson, Jamie McQueen, Paul Baxter, Kayalvizhi Sabari-Sankar, Jing Qiu, Xin He, Jill H. Fowler, James A. Febery, Jenna M. Gregory, Jamie Rose, Jane Tulloch, James JM Loan, David Story, Karina McDade, Amy Smith, Peta Greer, Matt Ball, Peter C. Kind, Paul M. Matthews, Colin Smith, Owen Dando, Tara L. Spires‐Jones, Jeffrey A. Johnson, Siddharthan Chandran, Giles E. Hardingham
Abstract
tauopathy mice revealed that only Aß influenced expression of AD risk genes, but both pathologies precociously induced age-dependent changes, and had distinct but overlapping signatures found in human post-mortem AD astrocytes. Both Aß and Tau pathology induced an astrocyte signature involving repression of bioenergetic and translation machinery, and induction of inflammation pathways plus protein degradation/proteostasis genes, the latter enriched in targets of inflammatory mediator Spi1 and stress-activated cytoprotective Nrf2. Astrocyte-specific Nrf2 expression induced a reactive phenotype which recapitulated elements of this proteostasis signature, reduced Aß deposition and phospho-tau accumulation in their respective models, and rescued brain-wide transcriptional deregulation, cellular pathology, neurodegeneration and behavioural/cognitive deficits. Thus, Aß and Tau induce overlapping astrocyte profiles associated with both deleterious and adaptive-protective signals, the latter of which can slow patho-progression.